Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) shot up 18.2% during trading on Tuesday . The stock traded as high as C$1.69 and last traded at C$1.62. 747,191 shares traded hands during trading, an increase of 455% from the average session volume of 134,529 shares. The stock had previously closed at C$1.37.
Wall Street Analyst Weigh In
Separately, Jones Trading lowered Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.
Check Out Our Latest Analysis on ONC
Oncolytics Biotech Stock Up 24.1%
The firm has a 50 day moving average price of C$0.76 and a 200-day moving average price of C$0.93. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The firm has a market cap of C$131.03 million, a price-to-earnings ratio of -4.74 and a beta of 1.35.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
